Excellent news by DMPI today......
.
In a press release put out by DMPI today, CEO Jeffrey Baccha states in part:
"Our data continues to demonstrate VAL-083's unique cytotoxic anti-cancer mechanism which may provide new treatment opportunities for patients whose cancer has failed or is unlikely to respond to currently available therapies. In particular, the data we have presented in our refractory GBM clinical trial positions us to advance this program into registration-directed Phase III clinical trials and we look forward to discussing our proposed trial design with the FDA," said Jeffrey Bacha, DelMar's chairman & CEO.
"Importantly, new funds raised subsequent to quarter end enable us to fund current operations through 2017 and help position DelMar to qualify to list its common stock on a senior exchange."
EXPECTED NEAR-TERM MILESTONES
•Apply to list our shares on a senior stock exchange;
•Engage the FDA regarding the design of a proposed registration-directed Phase II/III clinical trial for VAL-083 in refractory GBM;
•Initiate the Phase II clinical study at MD Anderson with VAL-083 in patients with GBM at first recurrence/progression;
•Initiate clinical studies in newly-diagnosed GBM patients as an alternative to temozolomide in patients with high expression of MGMT;
•Initiate new clinical trials with VAL-083 in refractory non-small cell lung cancer;
•Initiate registration-directed Phase II/III clinical trials for VAL-083 as a new treatment option for refractory GBM in 2016;
•Continue to pursue pre-clinical research with leading investigators to advance VAL-083 as a potential treatment for other chemo-resistant cancers including ovarian cancer and pediatric medulloblastoma;
•Maximize the value of the VAL-083 pipeline through potential partnering opportunities in high value oncology markets;
•Continue to build the Company's intellectual property portfolio; and
•Continue to implement strategies to enable DelMar to meet qualifications to list its shares on a senior stock exchange
